At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
HP802-247 +1 morebiological
Likely dose
Bacitracin Ointment 50 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Randomized, Open-label Study Investigating the Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients
In Brief
A Phase 2 clinical trial evaluating HP802-247 and Bacitracin Ointment for Non-melanoma Skin Cancer. Completed, enrolled 8 participants across 1 site.
Detailed Summary
This study compares HP802-247 versus an antibiotic ointment for healing the wound after Mohs surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-melanoma Skin Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2011
First PostedMay 2011
Primary CompletionNov 2011
Study CompletionMay 2012
TodayJul 2026
First PostedMay 25, 2011
Enrollment StartMay 1, 2011
Primary CompletionNov 1, 2011
Study CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 15.1 years ago
Interventions
HP802-247biological
High dose HP 802-247, applied at each visit (Week 1-13) or until healed
Bacitracin Ointmentbiological
One dose of Bacitracin ointment consists of 50 units/1 gram. This will be applied daily for 12 weeks (or until healed).